Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4616 Clinical characterisation of patients with familial midgut neuroendocrine tumours (FM-NETs) based on a comparison with the large population-based GTE/RENATEN cohort

Introduction: The clinical specificities of FM-NET have been poorly described.

Conference:

Presenting Author: Hunaut T

Authors: Hunaut T, Hercent A, Walter T, Buecher B, Lepage C,

Keywords: Small intestine neuroendocrine tumour, Familial carcinoid tumour,

#3962 Familial midgut neuroendocrine tumors (FM-NETs): Results of the nationwide TCF cohort from the GTE-RENATEN network

Introduction: The clinical specificities of familial midgut neuroendocrine tumors (FM-NET) have been poorly described.

Conference:

Presenting Author: de Mestier L

Authors: Hunaut T, Hercent A, Walter T, Buecher B, Lepage C,

Keywords: familial, midgut, neuroendocrine, tumors, carcinoid,

#3791 Trends in neuroendocrine-related searches on Google – How famous cases impact on interest of general population

Introduction: General population interest in neuroendocrine tumors (NET) is influenced by mass-media news and awareness campaigns by advocacy and medical groups. Cases of NET in famous people greatly impact conversations about this disease.

Conference:

Presenting Author:

Authors: Hernando Cubero J, Garcia Alvarez A, Roca-Herrera M, Carmona Alonso A, Garcia Burillo A,

Keywords: Google, Trends, Famous,

#3487 Circulating cell free tumor DNA as a biomarker in patients with neuroendocrine neoplasms

Introduction: There is a need to develop better biomarkers to monitor patients with neuroendocrine neoplasms (NENs).

Conference:

Presenting Author:

Authors: Gohil S, Hastings R, Page K, Iwuji C, Richards C,

Keywords: neuroendocrine, circulating cell free tumor derived DNA, ctDNA, biomarker, next generation sequencing, cell free DNA, PRRT,

#3303 Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumors - An international double-blind, placebo-controlled randomized phase 2. Prodige 31 REMINET. A FFCD study

Introduction: Following European guidelines, patients (pts) with aggressive metastatic or locally advanced, non-resectable, duodeno-pancreatic (DP) neuroendocrine tumors (NETs), should receive systemic combination of chemotherapy until progression. Aggressive disease is defined as progressive and/or symptomatic metastases and/or with significant hepatic invasion (>30-50%), and/or bone metastases.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Lepage C

Authors: Lepage C, Phelip J, Lievre A, Le Malicot K, Dahan L,

Keywords: clinical trial, non-resectable, duodeno-pancreatic, neuroendocrine tumor, maintenance,